References of "BECK, Emmanuel"
     in
Bookmark and Share    
Full Text
See detailPituitary magnetic resonance imaging in gigantism : first result after analysis of 16 cases
BECK, Emmanuel ULg; KREUTZ, Julie ULg; TSHIBANDA, Luaba ULg et al

in 23rs meeting of the Belgian Endocrine Society - Abstract book (2013, October 19)

Detailed reference viewed: 21 (4 ULg)
Full Text
Peer Reviewed
See detailThrombose portale étendue chez un patient sous anti-vitamine K
LEDOUBLE, Vinciane ULg; BECK, Emmanuel ULg; PETERS, Pierre ULg et al

in Revue Médicale de Liège (2013), (68(7-8)), 382-6

Detailed reference viewed: 40 (6 ULg)
Full Text
Peer Reviewed
See detailL’enzyme11β-HSD1 : une nouvelle cible potentielle pour le traitement du diabète de type 2 et des maladies métaboliques liées à l’obésité
SCHEEN, André ULg; BECK, Emmanuel ULg

in Diabète et Obésité (2013), 8

The 11 beta-hydroxysteroid dehydrogenase type 1 (11βHSD1) enzyme promotes the local conversion from cortisone to cortisol, especially in the adipose tissue and the liver. It may play a role in the ... [more ▼]

The 11 beta-hydroxysteroid dehydrogenase type 1 (11βHSD1) enzyme promotes the local conversion from cortisone to cortisol, especially in the adipose tissue and the liver. It may play a role in the pathophysiology of abdominal obesity and the metabolic syndrome, both showing some similarities with the Cushing syndrome. Synthetic selective inhibitors of 11βHSD1 are currently in development with encouraging preliminary results that remain, however, to be further improved. Selective inhibitors of 11βHSD1 may represent an innovative approach in the pharmacological management of obesity, metabolic syndrome and type 2 diabetes. [less ▲]

Detailed reference viewed: 24 (2 ULg)
Full Text
Peer Reviewed
See detailLa metformine: une molecule antidiabetique dotee de proprietes anti-cancereuses.
BECK, Emmanuel ULg; Scheen, André ULg

in Revue medicale de Liege (2013), 68(9), 444-9

Numerous epidemiological cohort and case-control studies showed that type 2 diabetes is a risk factor for cancer and that metformin therapy is associated with a significant reduction in the incidence of ... [more ▼]

Numerous epidemiological cohort and case-control studies showed that type 2 diabetes is a risk factor for cancer and that metformin therapy is associated with a significant reduction in the incidence of cancer and cancer-related death when compared to other glucose-lowering agents. Such beneficial effect is observed whatever the type of cancer, but seems to be more prominent in case of gastrointestinal and breast cancers. In general, the protective effect was more evident in observational cohort studies (however, more exposed to bias due to confounding factors) than in case-control studies. However, the results of the rather rare controlled clinical trials available are not conclusive, but none of them was performed with the objective to specifically assess cancer risk. Several meta-analyses recently confirmed that metformin therapy reduces the incidence of cancers (including colorectal cancer, hepatocarcinoma, breast cancer) and cancer-related mortality. Metformin may exert its anti-cancer activity by a direct effect (insulin) and an indirect effect (AMPK and mTOR). Considering all promising clinical information in patients with type 2 diabetes, further clinical trials are currently ongoing with the aim of assessing the role of metformin in oncology, especially as adjuvant in breast cancer therapy. [less ▲]

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailHypocortisolism induces chronic respiratory failure
PIRLET, Charles ULg; BECK, Emmanuel ULg; SCHEEN, André ULg et al

in Respiratory Medicine (2011), 4(3), 107-108

Hypocortisolism is an uncommon condition. Its association with myopathy and respiratoryfailure has only rarely been described. We report the case of a 52 year-old woman presenting with progressive ... [more ▼]

Hypocortisolism is an uncommon condition. Its association with myopathy and respiratoryfailure has only rarely been described. We report the case of a 52 year-old woman presenting with progressive dyspnoea. Work-up revealed a severe restrictive syndrome with hypoxaemia. Further investigations showed hypocortisolism of pituitary origin. Response to hydrocortisone allowed us to conclude to an unusual case of hypocortisolic myopathy affecting the respiratory muscles. [less ▲]

Detailed reference viewed: 50 (4 ULg)
Full Text
Peer Reviewed
See detailObesite, insulinoresistance et diabete de type 2: facteurs de risque du cancer du sein.
SCHEEN, André ULg; Beck, Emmanuel ULg; DE FLINES, Jenny ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 238-44

Obesity and type 2 diabetes are two risk factors of breast cancer, especially after menopause. Underlying mechanisms are multiple and include hyperinsulinism due to insulin resistance (insulin, as insulin ... [more ▼]

Obesity and type 2 diabetes are two risk factors of breast cancer, especially after menopause. Underlying mechanisms are multiple and include hyperinsulinism due to insulin resistance (insulin, as insulin-like-growth factor -IGF-, is a growth factor), hyperleptinaemia associated with hypoadiponectinaemia, and high levels of estrogens resulting from aromatization of androgens in adipose tissue. In presence of type 2 diabetes associated with obesity, hyperglycaemia might provide energy substrate promoting tumour growth. These data have therapeutic implications with expected favourable effects of weight loss, resulting in a reduction of fat mass and insulin resistance, and the promising results recently reported with metformin contrasting with the negative effects of exogenous administration of high doses of insulin. [less ▲]

Detailed reference viewed: 98 (5 ULg)
Full Text
Peer Reviewed
See detailActivite anticancereuse de la metformine: nouvelles perspectives pour une vieille molecule.
Beck, Emmanuel ULg; Scheen, André ULg

in Revue Médicale Suisse (2010), 6(260), 1601-7

Le diabète de type 2 est associé à un risque accru de cancer, d’autant plus évident qu’on maîtrise mieux la mortalité cardio-vasculaire. Tous les traitements antidiabétiques n’ont pas le même impact sur ... [more ▼]

Le diabète de type 2 est associé à un risque accru de cancer, d’autant plus évident qu’on maîtrise mieux la mortalité cardio-vasculaire. Tous les traitements antidiabétiques n’ont pas le même impact sur le cancer : le risque est accru avec les sulfonylurées et diminué avec la metformine (et les glitazones). De nombreuses études épidémiologiques observationnelles et cas-témoins récentes révèlent qu’un traitement par metformine est associé à une nette réduction de l’incidence de néoplasies et de la mortalité par cancer. Il existe une relation doseréponse et une relation entre la durée préalable du traitement par metformine et l’effet protecteur observé. Les mécanismes invoqués sont l’activation de l’enzyme AMPK et l’inhibition de la voie mTOR. Des études avec la metformine sont en cours en oncologie, notamment dans le cancer du sein. [less ▲]

Detailed reference viewed: 69 (2 ULg)
Full Text
Peer Reviewed
See detailSujets de poids normal «métaboliquement obèses» et sujets obèses «métaboliquement sains»
Beck, Emmanuel ULg; Esser, Nathalie; Paquot, Nicolas ULg et al

in Revue Médicale de la Suisse Romande (2009), 5

Les relations entre poids corporel et anomalies métaboliques ne sont pas univoques. Ainsi, il existe des personnes non obèses métaboliquement anormales (MONW), rarement dépistées en raison d’un poids ... [more ▼]

Les relations entre poids corporel et anomalies métaboliques ne sont pas univoques. Ainsi, il existe des personnes non obèses métaboliquement anormales (MONW), rarement dépistées en raison d’un poids corporel faussement rassurant, et, à l’inverse, des sujets métaboliquement sains bien qu’ils soient obè ses (MHO). La topographie (intra-abdominale/hépatique vs sous-cutanée périphérique) et l’activité hormono-métabolique et pro-inflammatoire différente des dépôts graisseux semblent jouer un rôle déterminant pour expliquer ce paradoxe. Cet article de revue vise à décrire les grands principes de la prise en charge thérapeutique des personnes MONW, dans le but de réduire le risque accru de diabète de type 2 et de maladies cardiovasculaires, et de discuter les avantages et inconvénients d’une prise en charge classique de l’obésité chez les patients MHO. [less ▲]

Detailed reference viewed: 70 (7 ULg)
Full Text
Peer Reviewed
See detail"Metaboliquement obeses" sans exces de poids: un phenotype interpellant.
Beck, Emmanuel ULg; Scheen, André ULg

in Revue Médicale de Liège (2009), 64(1), 14-22

Obesity, especially abdominal obesity, is the main risk factor of metabolic syndrome. However, there are obviously non obese individuals who are metabolically abnormal and therefore exposed to an ... [more ▼]

Obesity, especially abdominal obesity, is the main risk factor of metabolic syndrome. However, there are obviously non obese individuals who are metabolically abnormal and therefore exposed to an increased risk of cardiovascular complications. Unfortunately, those persons fail to be detected because of a falsely reassuring body weight. The present paper aims at better understanding the etiopathogenesis and pathophysiology of this particular phenotype, at evaluating its potential clinical consequences and at describing the main principles of its therapeutic management. [less ▲]

Detailed reference viewed: 52 (5 ULg)
Full Text
Peer Reviewed
See detailSujets « métaboliquement obèses » de poids normal. Première partie: diagnostic, physiopathologie et prévalence
Beck, Emmanuel ULg; Paquot, Nicolas ULg; Scheen, André ULg

in Obésité (2008), 3(3), 184-193

Obesity, particularly abdominal obesity, is the main risk factor for metabolic syndrome. However, some non-obese individuals are metabolically abnormal and therefore probably have an increased risk of ... [more ▼]

Obesity, particularly abdominal obesity, is the main risk factor for metabolic syndrome. However, some non-obese individuals are metabolically abnormal and therefore probably have an increased risk of cardiovascular disease. The present review paper aims to describe the main characteristics of the metabolically obese normal-weight (MONW) syndrome, analyse its etiopathogenesis and pathophysiology and, finally, assess its prevalence in various populations. [less ▲]

Detailed reference viewed: 74 (5 ULg)
Full Text
Peer Reviewed
See detailSujets « métaboliquement obèses » de poids normal. Seconde partie: pronostic et prise en charge
Beck, Emmanuel ULg; Paquot, Nicolas ULg; Scheen, André ULg

in Obésité (2008), 3(4), 280-285

Metabolically obese normal-weight (MONW) individuals are frequently not detected because of a falsely reassuring body weight. However, they have most of the metabolic syndrome markers known to be ... [more ▼]

Metabolically obese normal-weight (MONW) individuals are frequently not detected because of a falsely reassuring body weight. However, they have most of the metabolic syndrome markers known to be associated with a higher risk of type 2 diabetes, cardiovascular disease and mortality. The present review paper aims to describe the clinical consequences to which MONW people are exposed and the main principles of managing this syndrome [less ▲]

Detailed reference viewed: 41 (4 ULg)